TP53-altered acute myeloid leukemia and myelodysplastic syndrome with excess blasts should be approached as a single entity.
TP53
acute myeloid leukemia (AML)
cutoff
excess blasts
myelodysplastic syndrome (MDS)
p53
Journal
Cancer
ISSN: 1097-0142
Titre abrégé: Cancer
Pays: United States
ID NLM: 0374236
Informations de publication
Date de publication:
15 01 2023
15 01 2023
Historique:
revised:
28
07
2022
received:
23
05
2022
accepted:
19
09
2022
pubmed:
19
11
2022
medline:
24
12
2022
entrez:
18
11
2022
Statut:
ppublish
Résumé
TP53-altered myelodysplastic syndrome with excess blasts and TP53-altered acute myeloid leukemia should be considered under one unifying classification term for their study in clinical trials. Ultimately, such a unification would simplify the screening processes for clinical trials and allow a focus on treating the patient for a genetically defined disorder rather than one based on an arbitrary blast threshold.
Substances chimiques
TP53 protein, human
0
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
175-180Subventions
Organisme : NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
© 2022 American Cancer Society.
Références
Estey E, Hasserjian RP, Dohner H. Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal. Blood. 2022;139(3):323-332. doi:10.1182/blood.2021011304
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemia: integrating morphological, clinical, and genomic data. Blood. 2022;140(11):1200-1228. doi:10.1182/blood.2022015850
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022;36(7):1703-1719. doi:10.1038/s41375-022-01613-1
Papaemmanuil E, Gerstung M, Bullinger L, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209-2221. doi:10.1056/nejmoa1516192
Bernard E, Nannya Y, Hasserjian RP, et al. Implications of TP53 allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes. Nat Med. 2020;26(10):1549-1556. doi:10.1038/s41591-020-1008-z
Chen X, Othus M, Wood BL, et al. Comparison of myeloid blast counts and variant allele frequencies of gene mutations in myelodysplastic syndrome with excess blasts and secondary acute myeloid leukemia. Leuk Lymphoma. 2021;62(5):1226-1233. doi:10.1080/10428194.2020.1861267
Sill H, Zebisch A, Haase D. Acute myeloid leukemia and myelodysplastic syndromes with TP53 aberrations-a distinct stem cell disorder. Clin Cancer Res. 2020;26(20):5304-5309. doi:10.1158/1078-0432.ccr-20-2272
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the acute leukaemias. French-American-British (FAB) Co-Operative Group. Br J Haematol. 1976;33(4):451-458. doi:10.1111/j.1365-2141.1976.tb03563.x
Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol. 1982;51(2):189-199. doi:10.1111/j.1365-2141.1982.tb08475.x
Swerdlow SH, Campo E, Harris NL, et al., eds. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC; 2017.
Matsuda A, Germing U, Jinnai I, et al. Difference in clinical features between Japanese and German patients with refractory anemia in myelodysplastic syndromes. Blood. 2005;106(8):2633-2640. doi:10.1182/blood-2005-01-0040
Naqvi K, Jabbour E, Bueso-Ramos C, et al. IImplications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers. Blood. 2011;118(17):4690-4693. doi:10.1182/blood-2011-03-342642
Senent L, Arenillas L, Luno E, Ruiz JC, Sanz G, Florensa L. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes. Haematologica. 2013;98(4):568-575. doi:10.3324/haematol.2012.071449
Ades L, Dimicoli-Salazar S, Sebert M, et al. Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the IDEAL phase 2 study by the GFM group. Blood. 2021;138(suppl 1):63. doi:10.1182/blood-2021-147898
Sebert M, Cluzeau T, Beyne Rauzy O, et al. Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the IDIOME phase 2 study by the GFM group. Blood. 2021;138(suppl 1):62. doi:10.1182/blood-2021-146932
Badar T, Atallah E, Shallis RM, et al. Outcomes of TP53 mutated AML with evolving frontline therapies: impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022;97(7):E232-E235. doi:10.1002/ajh.26546
Weinberg OK, Siddon AJ, Madanat Y, et al. TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML. Blood Adv. 2022;6(9):2847-2853. doi:10.1182/bloodadvances.2021006239
Grob T, Al Hinai AS, Sanders MA, et al. Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood. 2022;139(15):2347-2354. doi:10.1182/blood.2021014472
Prochazka KT, Pregartner G, Rucker FG, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104(3):516-523. doi:10.3324/haematol.2018.205013
Rucker FG, Schlenk RF, Bullinger L, et al. TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome. Blood. 2012;119(9):2114-2121. doi:10.1182/blood-2011-08-375758
Kulasekararaj AG, Smith AE, Mian SA, et al. TP53 mutations in myelodysplastic syndrome are strongly correlated with aberrations of chromosome 5, and correlate with adverse prognosis. Br J Haematol. 2013;160(5):660-672. doi:10.1111/bjh.12203
Leung GMK, Zhang C, Ng NKL, et al. Distinct mutation spectrum, clinical outcome and therapeutic responses of typical complex/monosomy karyotype acute myeloid leukemia carrying TP53 mutations. Am J Hematol. 2019;94(6):650-657. doi:10.1002/ajh.25469
Shallis RM, Stahl M, Bewersdorf JP, Zeidan AM. The current understanding of and treatment paradigm for newly-diagnosed TP53-mutated acute myeloid leukemia. Hemato. 2021;2(4):748-763. doi:10.3390/hemato2040051
Bewersdorf JP, Shallis RM, Gowda L, et al. Clinical outcomes and characteristics of patients with TP53-mutated acute myeloid leukemia or myelodysplastic syndromes: a single center experience. Leuk Lymphoma. 2020;61(9):2180-2190. doi:10.1080/10428194.2020.1759051
Lindsley RC, Saber W, Mar BG, et al. Prognostic mutations in myelodysplastic syndrome after stem-cell transplantation. N Engl J Med. 2017;376(6):536-547. doi:10.1056/nejmoa1611604
Ciurea SO, Chilkulwar A, Saliba RM, et al. Prognostic factors influencing survival after allogeneic transplantation for AML/MDS patients with TP53 mutations. Blood. 2018;131(26):2989-2992. doi:10.1182/blood-2018-02-832360
Haase D, Stevenson KE, Neuberg D, et al. TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups. Leukemia. 2019;33(7):1747-1758. doi:10.1038/s41375-018-0351-2
Kim K, Maiti A, Loghavi S, et al. Outcomes of TP53-mutant acute myeloid leukemia with decitabine and venetoclax. Cancer. 2021;127(20):3772-3781. doi:10.1002/cncr.33689
Short NJ, Montalban-Bravo G, Hwang H, et al. Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia. Blood Adv. 2020;4(22):5681-5689. doi:10.1182/bloodadvances.2020003120
Sallman DA, Komrokji R, Vaupel C, et al. Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes. Leukemia. 2016;30(3):666-673. doi:10.1038/leu.2015.304
Montalban-Bravo G, Kanagal-Shamanna R, Benton CB, et al. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes. Blood Adv. 2020;4(3):482-495. doi:10.1182/bloodadvances.2019001101
Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognosis scoring system for myelodysplastic syndromes. NEJM Evid. 2022;1(7).
Ganster C, Schaab R, Shirneshan K, et al. TP53 status and outcome in myelodysplastic syndromes with complex aberrant karyotypes [abstract EP785]. Abstract presented at: 25th Congress of the European Hematology Association; June 12, 2020; Frankfurt, Germany.
Cherry EM, Abbott D, Amaya M, et al. Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia. Blood Adv. 2021;5(24):5565-5573. doi:10.1182/bloodadvances.2021005538
Grenet J, Jain AG, Burkart M, et al. Comparing outcomes between liposomal daunorubicin/cytarabine (CPX-351) and HMA+venetoclax as frontline therapy in acute myeloid leukemia [abstract 32]. Abstract presented at: 2021 American Society of Hematology Annual Meeting; December 11-13, 2021; Atlanta, GA.
DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and venetoclax in previously untreated acute myeloid leukemia. N Engl J Med. 2020;383(7):617-629. doi:10.1056/nejmoa2012971
Matthews AH, Perl AE, Luger SM, et al. Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia. Blood Adv. 2022;6(13):3997-4005. doi:10.1182/bloodadvances.2022007265
McGraw KL, Nguyen J, Komrokji RS, et al. Immunohistochemical pattern of p53 is a measure of TP53 mutation burden and adverse clinical outcome in myelodysplastic syndromes and secondary acute myeloid leukemia. Haematologica. 2016;101(8):e320-e323. doi:10.3324/haematol.2016.143214
Tashakori M, Kadia TM, Loghavi S, et al. TP53 copy number and protein expression inform mutation status across risk categories in acute myeloid leukemia. Blood. 2022;140(1):58-72. doi:10.1182/blood.2021013983
Dohner H, Wei AH, Appelbaum FR, et al. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022;140(12):1345-1377. doi:10.1182/blood.2022016867